CARsgen’s CAR-T Product Zevor-Cel Included in China’s Commercial Health Insurance Innovative Drug Catalogue

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced today announced with great pleasure that its independently developed fully human BCMA-targeted CAR-T product, zevorcabtagene autoleucel (zevor-cel, R&D code: CT053), has been included in China's Commercial Health Insurance Innovative Drug Catalogue (2025) (referred to as the “Innovative Drug […]

Funding Reaches $19.2M as Mutuum Finance (MUTM) Presale Moves Toward Full Allocation

DUBAI, United Arab Emirates, Dec. 07, 2025 (GLOBE NEWSWIRE) — Mutuum Finance (MUTM) has reached a new presale milestone, surpassing $19.2 million in funding as its ongoing offering approaches full allocation. With the current phase rapidly drawing to a close and development updates continuing to surface, the project is entering one of the most active

Funding Reaches $19.2M as Mutuum Finance (MUTM) Presale Moves Toward Full Allocation

Funding Reaches $19.2M as Mutuum Finance (MUTM) Presale Moves Toward Full Allocation GlobeNewswire December 07, 2025 DUBAI, United Arab Emirates, Dec. 07, 2025 (GLOBE NEWSWIRE) — Mutuum Finance (MUTM) has reached a new presale milestone, surpassing $19.2 million in funding as its ongoing offering approaches full allocation. With the current phase rapidly drawing to a

Texas Business Leader and Philanthropist Thomas O. Hicks Passes Away at Age 79

Thomas O. Hicks, legendary Texas businessman, philanthropist, mentor, and devoted husband and father, died peacefully yesterday in Dallas surrounded by his family. He was 79. https://mma.prnewswire.com/media/2839889/HICKS_HOLDING__Thomas_O_Hicks.jpg Hicks was widely regarded as a pioneer in American business, reshaping private equity and introducing strategies that influenced an entire generation of investors. He co-founded Hicks & Haas in

All Approved Indications of Five Akeso’s Innovative Drugs Included in China’s Latest NRDL: Featuring Two First-in-Class Bispecifics with New First-Line Indications and Three Newly Negotiated Drugs

Akeso, Inc. (9926.HK) (“Akeso” or the “Company”) announced the successful inclusion of all five of the Company's self-developed innovative drugs into the updated National Reimbursement Drug List (NRDL) for 2025, released by China's National Healthcare Security Administration (NHSA), effective January 1, 2026. These inclusions cover both newly added indications of previously included drugs, and as

Pixalate’s Q3 2025 Report Uncovers 1,248 APAC-Registered Mobile Apps Across Apple App & Google Play Stores Violating COPPA, Impacting 117 Million Child-App Users in USA

LONDON, Dec. 07, 2025 (GLOBE NEWSWIRE) — Pixalate today released the Q3 2025 State of Children's Privacy Risk Report for Asia-Pacific (APAC) Mobile Apps. The analysis reveals significant privacy gaps in mobile apps available for download on the Google Play Store and Apple App Store, likely violating the Children's Online Privacy Protection Act (COPPA) by

Pixalate’s Q3 2025 Report Uncovers 1,248 APAC-Registered Mobile Apps Across Apple App & Google Play Stores Violating COPPA, Impacting 117 Million Child-App Users in USA

Pixalate's Q3 2025 Report Uncovers 1,248 APAC-Registered Mobile Apps Across Apple App & Google Play Stores Violating COPPA, Impacting 117 Million Child-App Users in USA According to new research from Pixalate, 962 apps failed to provide the requisite 'children's privacy' disclosure as specified under COPPA; Out of 1,003 APAC-registered, ad-enabled, child-directed mobile apps analyzed, 1,001

Skymizerʼs HyperThought™ Wins “Best IP/Processor of the YearË® and “Most Promising ProductË® at EE Awards Asia 2025

Skymizer today announced that its next-generation HyperThought™ LLM Accelerator IP has been awarded “Best IP/Processor of the YearË® and named the “Most Promising ProductË® at the prestigious EE Awards Asia 2025, hosted by ASPENCORE at the Grand Mayfull Taipei Hotel. The dual recognition marks HyperThought as one of the most forward-looking semiconductor IP breakthroughs in

Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China’s National Reimbursement Drug List

Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that seven of its innovative products have been included in the updated 2025 National Reimbursement Drug List (NRDL). This list features a

Marex Group 48 Hour Deadline Alert: Former Louisiana Attorney General And Kahn Swick & Foti, LLC Remind Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Marex Group plc – MRX

NEW YORK CITY, NY AND NEW ORLEANS, LA / ACCESS Newswire / December 6, 2025 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until December 8, 2025 to file lead plaintiff applications in a securities class action lawsuit

Scroll to Top